Forecasts data is unavailable for this security.
Consensus recommendation
- 16-Nov-23
- 15-Aug-24
- 19-Sep-24
- 17-Oct-24
- 07-Nov-24
Select bar for recommendation details.
Recommendations | 07-Nov-24 | |
---|---|---|
Buy | 1 | |
Outperform | 1 | |
Hold | 3 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 5 analysts offering 12 month price targets for Theravance Biopharma Inc have a median target of 11.00, with a high estimate of 21.00 and a low estimate of 9.00. The median estimate represents a 23.04% increase from the last price of 8.94.
High | 134.9% | 21.00 |
Med | 23.0% | 11.00 |
Low | 0.7% | 9.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate | -10.89% |
Average growth rate | +15.35% |
More ▼
Revenue history & estimates in USD
Average growth rate | +1.73% |
Average growth rate | -5.12% |
More ▼